Biologic behavior and long-term outcomes of breast ductal carcinoma  in situ  with microinvasion

Yan Fang; Jiayi Wu; Wei Wang; Xiaochun Fei; Yu Zong; Xiaosong Chen; Ou Huang; Jianrong He; Weiguo Chen; Yafen Li; Kunwei Shen; Li Zhu

doi:10.18632/oncotarget.11639

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion

Yan Fang, Jiayi Wu, Wei Wang, Xiaochun Fei, Yu Zong, Xiaosong Chen, Ou Huang, Jianrong He, Weiguo Chen, Yafen Li, Kunwei Shen and Li Zhu _

PDF | HTML | How to cite

Oncotarget. 2016; 7:64182-64190. https://doi.org/10.18632/oncotarget.11639

Metrics: PDF 2405 views | HTML 3475 views | ?

Abstract

Yan Fang1,*, Jiayi Wu1,*, Wei Wang1, Xiaochun Fei2, Yu Zong1, Xiaosong Chen1, Ou Huang1, Jianrong He1, Weiguo Chen1, Yafen Li1, Kunwei Shen1, Li Zhu1

1Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China

2Department of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Li Zhu, email: [email protected]

Keywords: breast carcinoma, ductal carcinoma in situ, microinvasion, clinico-pathological feature, prognosis

Received: March 13, 2016 Accepted: August 13, 2016 Published: August 26, 2016

ABSTRACT

Background: Ductal carcinoma in situ with microinvasion (DCIS-Mi) generally has favorable prognosis, but the long-term outcomes of DCIS-Mi and the biologic evolution from ductal carcinoma in situ (DCIS), DCIS-Mi, to DCIS with T1a breast cancer (DCIS-T1a) has not been specified. The aim of our study was to explore the biological and prognostic features of DCIS-Mi, compared with pure DCIS and DCIS-T1a.

Results: After a median follow-up of 31 months, the 3-year estimated disease free survival(DFS) rate of DCIS-Mi patients was significantly lower than that of pure DCIS patients (89.5% vs 97.1%, P=0.009). Patients with DCIS-Mi or DCIS-T1a tumors had comparable 3-year estimated DFS rates (89.5% vs 94.3%, P=0.13). No significant difference in overall survival (OS) was found among different groups (99.6%, 100% and 99.1% for DCIS, DCIS-Mi and DCIS-T1a, P=0.797). In chemotherapy and trastuzumab-naive DCIS-Mi patients, human epidermal growth factor receptor2 (HER2) positivity (HR=21.8, 95%CI, 1.7-286.8, P=0.019) were independent predictor of worse DFS on multivariate analysis.

Methods: During September 2002 and December 2014, 602 breast cancer patients who underwent radical surgery were retrospectively reviewed. Three hundred and fifty-nine patients (59.6%) had pure DCIS, 84(14.0%) and 159(26.4%) were diagnosed as DCIS-Mi and DCIS-T1a. Clinico-pathological features were compared between different subgroups.

Conclusions: DCIS-Mi displayed a comparable survival to that of DCIS-T1a and a more aggressive biological nature than pure DCIS. Patients with HER2-positive DCIS-Mi had a worse survival and adjuvant chemotherapy plus target therapy needs to be further optimized in those patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11639

Publication Alerts

Research Papers:

Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion

Abstract